Reactive Dicarbonyl Scavengers Prevent Platelet Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing platelet activation are limited by the rapid activation of platelets after blood drawing, requiring analysis within 2 hours, which restricts large-scale testing and centralization in multicenter studies, and there is a need to prevent malondialdehyde modification of platelet proteins associated with diseases like metabolic syndrome and sickle cell disease.
Innovation Solution
Development of a method using novel LC/MS/MS analysis for measuring dilysyl-MDA crosslinks and administration of reactive dicarbonyl scavengers like salicylamine-related compounds to prevent the formation of malondialdehyde adducts, thereby inhibiting platelet activation and modifying proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If blood is drawn for platelet analysis, then platelet activation can be measured, but platelets activate rapidly after drawing requiring analysis within 2 hours which restricts large-scale testing and centralization
Solution Approach 1:
The patent applies preliminary action by adding inhibitors to blood collection tubes before phlebotomy to prevent platelet activation from the moment of collection. This pre-prepared protective environment allows blood samples to be stored and transported without activation, extending the analysis window from 2 hours to several days while maintaining measurement accuracy
Solution Approach 2:
The patent uses inhibitor compounds as intermediaries between the platelets and activating factors in the blood sample. These inhibitors act as mediators that block activation pathways, allowing the platelets to remain in an inactive state during storage and transport, thus enabling centralized analysis without compromising the integrity of the activation measurements
2Reliability
If current inhibitors are used at time of phlebotomy, then some platelet activation is prevented, but activation still occurs if tubes are not quickly used for analysis
Solution Approach 1:
The patent applies parameter changes by using multiple inhibitors with different mechanisms of action and duration profiles in combination. This multi-parameter approach ensures that platelet activation is blocked through multiple pathways simultaneously, providing robust prevention that maintains reliability over extended periods regardless of storage conditions or handling variations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables analysis of platelet activation up to 72 hours post-drawing, reduces platelet activation, and provides a therapeutic approach for diseases associated with increased platelet activation by preventing protein modifications.
Implementation Method 1
Compounds of the present invention were shown to react with MDA preferentially, thereby preventing formation of lysine adducts
Implementation Method 2
A reactive dicarbonyl, MDA forms covalent adducts of amino groups, including the ε-amine of lysine
Implementation Method 3
Utilizing a novel LC/MS/MS method for analysis of one of the MDA adducts, the dilysyl-MDA crosslink
Implementation Method 4
LC/MS/MS method for analysis of one of the MDA adducts
Implementation Method 5
The thromboxane synthase converts prostaglandin H2 to thromboxane A2 and malondialdehyde (MDA) in approximately equimolar amounts
Implementation Method 6
dilysyl-MDA crosslinks in human platelets are formed following platelet activation via the COX-1/thromboxane synthase pathway
Implementation Method 7
These protein modifications can be prevented by salicylamine-related scavengers
Implementation Method 8
method of preventing the formation of malondialdehyde adducts, comprising administering to a subject in need thereof an effective malondiadehyde adduct reducing amount of a of at least one γ-KA scavenger compound
Data Source
AI summary
A method of preventing or reducing the occurrence of malondiadehyde and/or levuglandin protein modification in a subject in need thereof, comprising administering to said subject an effective amount of at least one reactive dicarbonyl scavenger compound, or a pharmaceutically acceptable salt thereof.